TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22633825

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate, 64 mmol/day
Number of subjects: 1204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Magnesium (from meta-analysis)
Number of subjects: 1204
Study: 19341900

Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (non-EVAR treatment)
Number of subjects: 7
Study: 17929300

Group type: EXPERIMENTAL
Intervention: Ribavirin for 72 hours prior to peginterferon alpha‐2a injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a for 24 hours prior to biopsy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pretreatment group (matched control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: On treatment (RRs and SRs)
Number of subjects: 0
Study: 15164894

Group type: EXPERIMENTAL
Intervention: Prior sleep restriction condition (6 hours sleep per day for 7 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Prior sleep extension condition (12 hours sleep per day for 7 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Neurobehavioral testing during 36 hours of total sleep deprivation
Number of subjects: 21
Study: 10770145

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (50 to 200 mg/d, starting at 25 mg/d)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 9293218

Group type: EXPERIMENTAL
Intervention: Standard behavioral multicomponent program of Becoña
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Relapse prevention group (standard program + relapse prevention component)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (information session only)
Number of subjects: 75
Study: 8420682

Group type: EXPERIMENTAL
Intervention: Intraperitoneal phosphorus-32
Number of subjects: 24

Group type: COMPARATOR
Intervention: Three monthly cycles of cyclophosphamide and cisplatin
Number of subjects: 24
Study: 3552699

Group type: EXPERIMENTAL
Intervention: Single dose of 3 g cephalexin
Number of subjects: 86

Group type: COMPARATOR
Intervention: 3 days of cephalexin 1 g or combined preparation of pivmecillinam-pivampicillin
Number of subjects: 86
Study: 2566825

Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment for lesions due to Leishmania braziliensis guyanensis
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment for lesions due to Leishmania tropica
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: rIFN-gamma treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Histological and immunohistochemical studies
Number of subjects: 26
Study: 31984406

Group type: EXPERIMENTAL
Intervention: Micro total analysis system (μTAS) based on electrochemical measurements and dielectrophoretic sorting for screening of NAD(P)‐dependent oxidoreductases; specific details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Boron-doped diamond (BDD) electrode for high-throughput measurement of enzyme activity; specific details on dosage and duration not available.
Number of subjects: 0
Study: 31415008

Group type: EXPERIMENTAL
Intervention: Aromatherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 0
Study: 28852842

Group type: EXPERIMENTAL
Intervention: Combined nutraceutical supplement (one daily tablet containing phytoestrogens, vitamins, micronutrients, and passion flower herbal medicine) for 6 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined nutraceutical supplement
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 25274038

Group type: EXPERIMENTAL
Intervention: PSA screening every 4 years (cut-off 4 ng/ml)
Number of subjects: 80
Study: 24144057

Group type: EXPERIMENTAL
Intervention: Glycine (15 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21338741

Group type: EXPERIMENTAL
Intervention: Large portion size (300 g)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Small portion size (150 g)
Number of subjects: 17
Study: 19687576

Group type: EXPERIMENTAL
Intervention: Interferon-beta monotherapy for < or = 24 weeks
Number of subjects: 31
Study: 17005085

Group type: EXPERIMENTAL
Intervention: Kaixin Capsule (KXC) in combination with conventional Western medicine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional Western medicine (Control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (KXC and Control)
Number of subjects: 72
Study: 15546056

Group type: EXPERIMENTAL
Intervention: Acute day hospital treatment (87.7 days)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Conventional inpatient treatment (67.8 days)
Number of subjects: 191
Study: 11025891

Group type: EXPERIMENTAL
Intervention: Autocapture On (Group I, 81 patients)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Autocapture Off (Group II, 81 patients)
Number of subjects: 162
Study: 9570378

Group type: EXPERIMENTAL
Intervention: MVP
Number of subjects: 85

Group type: COMPARATOR
Intervention: PE
Number of subjects: 85
Study: 8447244

Group type: EXPERIMENTAL
Intervention: Single daily dose lithium
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multiple daily dose lithium
Number of subjects: 24
Study: 3533265

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg daily for five weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Clonidine (0.25 mg daily for five weeks)
Number of subjects: 26
Study: 30567725

Group type: EXPERIMENTAL
Intervention: 20 mg/m2 of IV decitabine on days 1 to 10 for up to 4 10-day cycles followed by monthly 5-day cycles
Number of subjects: 64

Group type: COMPARATOR
Intervention: 1.3 mg/m2 of subcutaneous bortezomib on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles
Number of subjects: 64
Study: 27311915

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (KE)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional anaesthetics (high dose midazolam, thiopental and/or propofol)
Number of subjects: 57
Study: 25855109

Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol (800 mcg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Hospital administration of vaginal misoprostol (800 mcg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Hospital administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Home self administration of vaginal misoprostol
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Use of extra dose of misoprostol
Number of subjects: 188
Study: 22883359

Group type: EXPERIMENTAL
Intervention: 1:5 diluted Buckley's formocresol (FC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ankaferd Blood Stopper(®) (ABS)
Number of subjects: 30
Study: 19536451

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 20
Study: 18772860

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sera from patients treated with nebivolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 40
Study: 16004737

Group type: EXPERIMENTAL
Intervention: Nurse-led secondary prevention clinics
Number of subjects: 36
Study: 12952150

Group type: EXPERIMENTAL
Intervention: Gutter Frame with Supplemental Oxygen (GFSO)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Gutter Frame with Supplemental Air (GFSA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rollator with Supplemental Air (RSA)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rollator with Supplemental Oxygen (RSO)
Number of subjects: 110
Study: 10698807

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 152
Study: 9379654

Group type: EXPERIMENTAL
Intervention: Pattern reversal (pr) stimulation in group III (20 years and more)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pattern flash (pf) stimulation in group III (20 years and more)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pattern flash (pf) stimulation in group II (11-20 years)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (40 healthy age-matched males, not exposed to leaded petrol)
Number of subjects: 90
Study: 8368548

Group type: EXPERIMENTAL
Intervention: Fast injection (FI) of isobaric 0.5% bupivacaine (2 mL during 2 to 3 s or approximately 0.75 mL/s)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slow injection (SI) of isobaric 0.5% bupivacaine (1 mL/min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fast reinjection (FI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Slow reinjection (SI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Duration of sensory block in FI group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Duration of sensory block in SI group
Number of subjects: 40
Study: 3519897

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolysis (streptokinase)
Number of subjects: 302
Study: 31473189

Group type: EXPERIMENTAL
Intervention: CCTG-led trials initiated post-2003
Number of subjects: 34957

Group type: COMPARATOR
Intervention: CCTG-led trials initiated pre-2003
Number of subjects: 34957

Group type: COMPARATOR
Intervention: Studies with exclusion criteria based on renal dysfunction
Number of subjects: 34957

Group type: EXPERIMENTAL
Intervention: Central nervous system studies
Number of subjects: 34957
Study: 31856840

Group type: EXPERIMENTAL
Intervention: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a long interval (8-12 weeks)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a short interval (4-7 weeks)
Number of subjects: 160
Study: 26961539

Group type: EXPERIMENTAL
Intervention: LCZ696 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LCZ696 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LCZ696 400 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All doses of LCZ696
Number of subjects: 40
Study: 25314578

Group type: EXPERIMENTAL
Intervention: Whole-body cryostimulation (WBC) daily during intensified training (ITWBC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ITCON) without WBC
Number of subjects: 10
Study: 23249889

Group type: EXPERIMENTAL
Intervention: Distally locked long cephalomedullary nails
Number of subjects: 11

Group type: COMPARATOR
Intervention: Unlocked long cephalomedullary nails
Number of subjects: 11
Study: 21667042

Group type: EXPERIMENTAL
Intervention: GS-9450 (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 10
Study: 19618579

Group type: EXPERIMENTAL
Intervention: Inclined stage (posterior incline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined stage (anterior incline)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined stage (posterior)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined stage (anterior)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined stage (lateral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inclined stage (medial)
Number of subjects: 8
Study: 17004188

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LAP)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Open surgery (CON)
Number of subjects: 147
Study: 14529335

Group type: EXPERIMENTAL
Intervention: Preformed metal crown (SSC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Cast adhesive coping (CAC)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Comparison of SSC and CAC
Number of subjects: 17
Study: 10843174

Group type: EXPERIMENTAL
Intervention: Continued GH therapy (0.018 +/- 0.001 mg/kg day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Open phase GH therapy (0.016 mg/kg x day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continued GH treatment
Number of subjects: 18
Study: 8809516

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2052198

Group type: EXPERIMENTAL
Intervention: IV atropine (1.3 to 29.9 micrograms/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV atropine (2.6 micrograms/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV atropine (29.9 micrograms/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6686808

Group type: EXPERIMENTAL
Intervention: Liquid antacids (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment with anticholinergic and antacids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antacids (high dose)
Number of subjects: 0
Study: 30649049

Group type: EXPERIMENTAL
Intervention: Unplanned pregnancy
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Ambivalent pregnancy
Number of subjects: 459

Group type: COMPARATOR
Intervention: Planned pregnancy
Number of subjects: 459
Study: 28521867

Group type: EXPERIMENTAL
Intervention: Single bout of moderate aerobic exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 12
Study: 25477278

Group type: EXPERIMENTAL
Intervention: 3D documentation system using Tumor Therapy Manager (TTM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional panendoscopy without TTM
Number of subjects: 42
Study: 24406481

Group type: EXPERIMENTAL
Intervention: Sibutramine treatment (6-week period)
Number of subjects: 9804

Group type: EXPERIMENTAL
Intervention: Long-term sibutramine treatment
Number of subjects: 9804

Group type: EXPERIMENTAL
Intervention: Weight loss and blood pressure reduction
Number of subjects: 9804

Group type: EXPERIMENTAL
Intervention: Weight gain and blood pressure increase
Number of subjects: 9804
Study: 21971125

Group type: EXPERIMENTAL
Intervention: Direct Lateral Interbody Fusion (DLIF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Anterior Lumbar Interbody Fusion (ALIF) with bilateral pedicle screw fixation (PSF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Direct Lateral Interbody Fusion (DLIF) with bilateral PSF
Number of subjects: 8

Group type: COMPARATOR
Intervention: ALIF and DLIF groups supplemented with bilateral PSF
Number of subjects: 8
Study: 19582880

Group type: EXPERIMENTAL
Intervention: CD163-positive tumors (n=10 out of 101 patients)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (5 x 5 Gy delivered in 1 week)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Nonirradiated group (n=78)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: CD163-positive tumors
Number of subjects: 163
Study: 17131132

Group type: EXPERIMENTAL
Intervention: Gelclair
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard therapy (Sucralfate and Mucaine)
Number of subjects: 20
Study: 15267128

Group type: EXPERIMENTAL
Intervention: Multinomial model
Number of subjects: 0
Study: 12685918

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0
Study: 9822094

Group type: EXPERIMENTAL
Intervention: Group I exercise protocol
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group II exercise protocol (more intense)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group D exercise protocol (diabetic subjects)
Number of subjects: 34
Study: 8739659

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (specifics not detailed, but includes alprazolam for a subgroup of 26 patients)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Alprazolam (subgroup of 26 patients)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Panic disorder subgroup with agoraphobia (n = 24)
Number of subjects: 47
Study: 2183864

Group type: EXPERIMENTAL
Intervention: Extradural pethidine 50 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.m. pethidine 100 mg
Number of subjects: 30
Study: 7416061

Group type: EXPERIMENTAL
Intervention: 10-day modified fast with fluid intake of 2.7 to 3 liters/day containing around 200 kcal from juices and teas
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10-day modified fast
Number of subjects: 12
Study: 31606835

Group type: EXPERIMENTAL
Intervention: UV-irradiated sporulated oocysts
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Non-irradiated sporulated oocysts
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-immunized/challenged control (NIC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-immunized/non-challenged control (NC)
Number of subjects: 144
Study: 28597198

Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 162
Study: 26295650

Group type: EXPERIMENTAL
Intervention: SAFIRE S4
Number of subjects: 51

Group type: COMPARATOR
Intervention: FBP
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose (260 mAs)
Number of subjects: 51
Study: 24586897

Group type: EXPERIMENTAL
Intervention: Treatment Plus Automated Emails Group (TEG)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Standard Treatment Group (TG)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Delayed-Treatment Waitlist Control Group (Control)
Number of subjects: 257
Study: 22929542

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with stepwise increases of PEEP achieving 45 cmH2O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to static compliance.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (ARDSNet strategy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with stepwise increases of PEEP
Number of subjects: 0
Study: 20231532

Group type: EXPERIMENTAL
Intervention: Active treatment (5 mg folic acid, 50 microg vitamin B(12), 20 mg vitamin B(6))
Number of subjects: 650

Group type: COMPARATOR
Intervention: Placebo (0.2 mg folic acid, 4 microg vitamin B(12), 1.0 mg vitamin B(6))
Number of subjects: 650
Study: 17430744

Group type: EXPERIMENTAL
Intervention: Natural laxative mixture (Beverley-Travis), 2 tablespoons twice a day for 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prescribed laxatives (control group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Natural laxative mixture
Number of subjects: 45
Study: 16302356

Group type: EXPERIMENTAL
Intervention: Supervised physiotherapist cycling training (3-4 times a week for 45 minutes over 8 weeks)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Not supervised training (cycling, stepping on stairs, or dynamic walking at home with the same duration and frequency)
Number of subjects: 54
Study: 11932294

Group type: EXPERIMENTAL
Intervention: T enanthate (TE) 250 mg/wk im plus ethinylestradiol (EE2) 0.1 mg/d orally for 5.8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: T enanthate (TE) alone
Number of subjects: 41
Study: 11006054

Group type: EXPERIMENTAL
Intervention: 1 additional risk factor
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: 2 additional risk factors
Number of subjects: 2149

Group type: COMPARATOR
Intervention: smoker only
Number of subjects: 2149

Group type: EXPERIMENTAL
Intervention: baseline risk factor status
Number of subjects: 2149
Study: 7612363

Group type: COMPARATOR
Intervention: Intravenous ranitidine 50 mg initially, followed by 50 mg every 6 hours
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Intravenous omeprazole 80 mg bolus initially, followed by 40 mg every 8 hours for 48 hours, then 40 mg every 12 hours until discharge
Number of subjects: 519
Study: 2371367

Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium amytal (250 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Haloperidol (10 mg)
Number of subjects: 15
Study: 889069

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nalorphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naloxone (high doses)
Number of subjects: 30
Study: 30964335

Group type: EXPERIMENTAL
Intervention: Diab and Nano videogames (9 sessions, ∼60 minutes each)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 200
Study: 29077022

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day for six days)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (carboxymethyl cellulose)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26005337

Group type: EXPERIMENTAL
Intervention: Experimental group (n=31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (n=33)
Number of subjects: 64
Study: 23893464

Group type: EXPERIMENTAL
Intervention: CT screening intervention
Number of subjects: 32000
Study: 21739497

Group type: EXPERIMENTAL
Intervention: Vaginal micronized progesterone
Number of subjects: 677

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 677
Study: 20135885

Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA)
Number of subjects: 0
Study: 16728524

Group type: EXPERIMENTAL
Intervention: Physical fitness (more-fit individuals)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Soluble ICAM-1
Number of subjects: 37
Study: 15144469

Group type: EXPERIMENTAL
Intervention: Birch-pollen immunotherapy (IT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Symptomatic drugs only (Control)
Number of subjects: 25
Study: 11776511

Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 3 cm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional embryo transfer (ET)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 5 cm
Number of subjects: 60